UNCY UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: .

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit  and follow us on  and .

Investor Contact:

Kevin Gardner

LifeSci Advisors

Media Contact:

Layne Litsinger

Real Chemistry

SOURCE: Unicycive Therapeutics, Inc.



EN
09/04/2026

Underlying

UNCYUNICYCIVE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNICYCIVE THERAPEUTICS INC

 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual H...

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Inve...

7h / 3m 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces Full Year 2025 Financial Results and ...

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Uni...

March 30, 2026 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim...

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on th...

February 4, 2026 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthan...

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...

January 29, 2026 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbon...

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmissi...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch